Free tool · No account
Clinical trials for stomach cancer
Stomach (gastric) cancer trials increasingly test targeted therapies for tumors with markers like HER2 or Claudin 18.2. A recent biomarker report helps focus the search.
705 recruiting trials. Showing a sample.
- recruitingPhase 2NCT07294664
PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory...
Listed by the study for Advanced Gastric Cancer. Record updated 2026-09-01.
Sponsored by The First Affiliated Hospital of Zhengzhou UniversityFull details on ClinicalTrials.gov → - recruitingPhase 1NCT06910657
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cel...
Listed by the study for Gastric Cancer. Record updated 2026-08-05.
Sponsored by ViroMissile, Inc.Full details on ClinicalTrials.gov → - recruitingEARLY_Phase 1NCT07166263
Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and eff...
Listed by the study for Gastric Cancer (GC). Record updated 2026-10-01.
Sponsored by Base Therapeutics (Shanghai) Co., Ltd.Full details on ClinicalTrials.gov → - recruitingNANCT06055387
Frailty Assessment and Intervention in Elderly Patients with Gastric Cancer Receiving Gastrectomy and Adjuvant Chemotherapy
Gastric cancer ranks among the top ten leading causes of death in Taiwan. Radical surgery is the sole curative method for gastric cancer. However, our previous research has revealed that elderly gastric cancer patients undergoing radical surgery face a significantly elevated r...
Listed by the study for Gastric Cancer. Record updated 2025-02-13.
Sponsored by Chang Gung Memorial HospitalFull details on ClinicalTrials.gov → - recruitingNCT04949737
Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies
Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (t...
Listed by the study for Stomach Neoplasms. Record updated 2026-03-31.
Sponsored by University Hospital Center of MartiniqueFull details on ClinicalTrials.gov → - recruitingPhase 2, Phase 3NCT06232434
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II
It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg (2000 mg in terms of prospidium chloride) in patient...
Listed by the study for Gastric Cancer With Peritoneal Dissemination. Record updated 2025-06-22.
Sponsored by Research Institute for Physical Chemical Problems of the Belarusian State UniversityFull details on ClinicalTrials.gov → - recruitingNCT06662110
IMmune Proteomics to Predict neoAdjuvant Chemotherapy and immunoTherapy Response in Gastric Cancer
The overall efficacy of neoadjuvant treatment for advanced gastric cancer is limited due to significant heterogeneity in patient responses. While neoadjuvant therapy offers hope for improved clinical outcomes, the key challenge is accurately predicting individual treatment res...
Listed by the study for Gastric Cancer, Gastroesophageal Junction Cancer. Record updated 2024-10-28.
Sponsored by Shanghai Zhongshan HospitalFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04771520
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop th...
Listed by the study for Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8. Record updated 2026-06-11.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingPhase 3NCT07315750
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction A...
Listed by the study for Gastric Carcinoma. Record updated 2026-09-22.
Sponsored by RemeGen Co., Ltd.Full details on ClinicalTrials.gov → - recruitingNANCT05356520
Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction
The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the ...
Listed by the study for Siewert Type II Adenocarcinoma of Esophagogastric Junction. Record updated 2024-11-08.
Sponsored by Xijing Hospital of Digestive DiseasesFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this stomach cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.